RxDoctor Payments Data

Nancy Johnson

Psychiatric/Mental Health · Pointblank, TXNPI 1053913392

Payments from drug & device makers

$2,241in general payments, 2019–2025

Across 119 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$397
  • Teva Pharmaceuticals USA, Inc.$367
  • Axsome Therapeutics, Inc.$237
  • Otsuka America Pharmaceutical, Inc.$172
  • Johnson & Johnson$153
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$150
  • plus $765 from 11 others

What the payments were for

  • Food & beverage$2,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,241 in reported general payments places this provider in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$5,543
Medicare patients
22
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine24$165,428
Invega TrinzaPaliperidone Palmitate14$124,968
VraylarCariprazine Hcl28$47,346
Invega SustennaPaliperidone Palmitate13$33,821
RexultiBrexpiprazole12$31,699
Quetiapine Fumarate ErQuetiapine Fumarate20$4,289
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$3,114
Divalproex Sodium ErDivalproex Sodium65$2,894
Aripiprazole63$2,794
Quetiapine Fumarate84$2,418
Mirtazapine133$1,742
Oxcarbazepine27$1,680
Lamotrigine91$1,253
Bupropion XlBupropion Hcl85$1,169
Prazosin Hcl23$1,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$367$165,42824 claims
Johnson & JohnsonInvega Trinza, Invega Sustenna$153$158,78927 claims
AbbVieVraylar$397$47,34628 claims
Otsuka America Pharmaceutical, Inc.Rexulti$172$31,69912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Pointblank

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →